UNLABELLED: Sirtuin1 (SIRT1) regulates central metabolic functions such as lipogenesis, protein synthesis, gluconeogenesis, and bile acid (BA) homeostasis through deacetylation. Here we describe that SIRT1 tightly controls the regenerative response of the liver. We performed partial hepatectomy (PH) to transgenic mice that overexpress SIRT1 (SIRT). SIRT mice showed increased mortality, impaired hepatocyte proliferation, BA accumulation, and profuse liver injury after surgery. The damaging phenotype in SIRT mice correlated with impaired farnesoid X receptor (FXR) activity due to persistent deacetylation and lower protein expression that led to decreased FXR-target gene expression; small heterodimer partner (SHP), bile salt export pump (BSEP), and increased Cyp7A1. Next, we show that 24-norUrsodeoxycholic acid (NorUDCA) attenuates SIRT protein expression, increases the acetylation of FXR and neighboring histones, restores trimethylation of H3K4 and H3K9, and increases miR34a expression, thus reestablishing BA homeostasis. Consequently, NorUDCA restored liver regeneration in SIRT mice, which showed increased survival and hepatocyte proliferation. Furthermore, a leucine-enriched diet restored mammalian target of rapamycin (mTOR) activation, acetylation of FXR and histones, leading to an overall lower BA production through SHP-inhibition of Cyp7A1 and higher transport (BSEP) and detoxification (Sult2a1) leading to an improved liver regeneration. Finally, we found that human hepatocellular carcinoma (HCC) samples have increased presence of SIRT1, which correlated with the absence of FXR, suggesting its oncogenic potential. CONCLUSION: We define SIRT1 as a key regulator of the regenerative response in the liver through posttranscriptional modifications that regulate the activity of FXR, histones, and mTOR. Moreover, our data suggest that SIRT1 contributes to liver tumorigenesis through dysregulation of BA homeostasis by persistent FXR deacetylation.
UNLABELLED: Sirtuin1 (SIRT1) regulates central metabolic functions such as lipogenesis, protein synthesis, gluconeogenesis, and bile acid (BA) homeostasis through deacetylation. Here we describe that SIRT1 tightly controls the regenerative response of the liver. We performed partial hepatectomy (PH) to transgenic mice that overexpress SIRT1 (SIRT). SIRTmice showed increased mortality, impaired hepatocyte proliferation, BA accumulation, and profuse liver injury after surgery. The damaging phenotype in SIRTmice correlated with impaired farnesoid X receptor (FXR) activity due to persistent deacetylation and lower protein expression that led to decreased FXR-target gene expression; small heterodimer partner (SHP), bile salt export pump (BSEP), and increased Cyp7A1. Next, we show that 24-norUrsodeoxycholic acid (NorUDCA) attenuates SIRT protein expression, increases the acetylation of FXR and neighboring histones, restores trimethylation of H3K4 and H3K9, and increases miR34a expression, thus reestablishing BA homeostasis. Consequently, NorUDCA restored liver regeneration in SIRTmice, which showed increased survival and hepatocyte proliferation. Furthermore, a leucine-enriched diet restored mammalian target of rapamycin (mTOR) activation, acetylation of FXR and histones, leading to an overall lower BA production through SHP-inhibition of Cyp7A1 and higher transport (BSEP) and detoxification (Sult2a1) leading to an improved liver regeneration. Finally, we found that humanhepatocellular carcinoma (HCC) samples have increased presence of SIRT1, which correlated with the absence of FXR, suggesting its oncogenic potential. CONCLUSION: We define SIRT1 as a key regulator of the regenerative response in the liver through posttranscriptional modifications that regulate the activity of FXR, histones, and mTOR. Moreover, our data suggest that SIRT1 contributes to liver tumorigenesis through dysregulation of BA homeostasis by persistent FXR deacetylation.
Authors: Mercedes Vázquez-Chantada; Usue Ariz; Marta Varela-Rey; Nieves Embade; Nuria Martínez-Lopez; David Fernández-Ramos; Laura Gómez-Santos; Santiago Lamas; Shelly C Lu; M Luz Martínez-Chantar; José M Mato Journal: Hepatology Date: 2009-02 Impact factor: 17.425
Authors: N Beraza; Y Malato; S Vander Borght; C Liedtke; H E Wasmuth; M Dreano; R de Vos; T Roskams; C Trautwein Journal: Gut Date: 2008-05 Impact factor: 23.059
Authors: Neil B Ruderman; X Julia Xu; Lauren Nelson; José M Cacicedo; Asish K Saha; Fan Lan; Yasuo Ido Journal: Am J Physiol Endocrinol Metab Date: 2010-01-26 Impact factor: 4.310
Authors: Rozalyn M Anderson; Jamie L Barger; Michael G Edwards; Kristina H Braun; Clare E O'Connor; Tomas A Prolla; Richard Weindruch Journal: Aging Cell Date: 2007-11-21 Impact factor: 9.304
Authors: Marina Maria Bellet; Selma Masri; Giuseppe Astarita; Paolo Sassone-Corsi; Maria Agnese Della Fazia; Giuseppe Servillo Journal: J Biol Chem Date: 2016-09-15 Impact factor: 5.157
Authors: Ian M Johnston; Jonathan D Nolan; Sanjeev S Pattni; Richard N Appleby; Justine H Zhang; Sarah L Kennie; Gaganjit K Madhan; Sina Jameie-Oskooei; Shivani Pathmasrirengam; Jeremy Lin; Albert Hong; Peter H Dixon; Catherine Williamson; Julian R F Walters Journal: Am J Gastroenterol Date: 2016-02-09 Impact factor: 10.864
Authors: Sarmistha Mukherjee; Karthikeyani Chellappa; Andrea Moffitt; Joan Ndungu; Ryan W Dellinger; James G Davis; Beamon Agarwal; Joseph A Baur Journal: Hepatology Date: 2016-12-24 Impact factor: 17.425
Authors: Jiansheng Huang; Andrew E Schriefer; Paul F Cliften; Dennis Dietzen; Sakil Kulkarni; Sucha Sing; Satdarshan P S Monga; David A Rudnick Journal: Am J Pathol Date: 2016-01-06 Impact factor: 4.307